Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Experimental Study Product Clear all
Withdrawn Phase 4 Interventional

Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age

NCT03481894
View directory record Official record
Conditions
Malnutrition
Interventions
Kabiven®, Compounded standard parenteral nutrition
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
2 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

Stannsoporfin With Light Therapy for Newborn Babies With Jaundice

NCT01887327
View directory record Official record
Conditions
Jaundice, Neonatal, Hyperbilirubinemia, Neonatal
Interventions
Phototherapy, Stannsoporfin, Placebo
Procedure · Drug
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Industry
Eligibility
1 Hour to 72 Hours
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
18
States / cities
Colton, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD6423 SAD/MAD Study in Healthy Volunteers

NCT01926366
View directory record Official record
Conditions
Healthy Volunteers.
Interventions
AZD6423, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
Not listed
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2014 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

NCT02035605
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

NCT03818802
View directory record Official record
Conditions
Healthy Elderly Volunteers
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Results available

Sequenced Therapies for Comorbid and Primary Insomnias

NCT01651442
View directory record Official record
Conditions
Insomnia Comorbid to Psychiatric Disorder, Primary Insomnia
Interventions
Behavioral Insomnia Therapy, Zolpidem, Trazodone, Cognitive Therapy
Behavioral · Drug
Lead sponsor
Jack Edinger, PhD
Other
Eligibility
21 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 21, 2026, 9:37 AM EDT
Terminated Phase 1 Interventional

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL

NCT04049383
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia
Interventions
CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 21, 2026, 9:37 AM EDT
Active, not recruiting Phase 3 Interventional

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

NCT03803553
View directory record Official record
Conditions
Metastatic Colon Cancer, Stage III Colon Cancer
Interventions
FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol, Encorafenib/Binimetinib/Cetuximab Protocol, Trastuzumab + Pertuzumab
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

NCT02738931
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir 50 mg tablet, Lamivudine 300 mg tablet, Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA), Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 21, 2026, 9:37 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

NCT04083781
View directory record Official record
Conditions
Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
Concizumab
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Orange, California • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 4 Interventional Results available

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

NCT03890666
View directory record Official record
Conditions
Asthma
Interventions
Albuterol eMDPI DS, albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Stockton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 3 Interventional Results available

The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)

NCT02510261
View directory record Official record
Conditions
Amyloidosis
Interventions
Patisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 21, 2026, 9:37 AM EDT
Terminated Phase 1 Interventional

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

NCT01541670
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Los Angeles, California • Yuba City, California • Centennial, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

NCT01473901
View directory record Official record
Conditions
Glioblastoma
Interventions
BKM120 + temozolomide, BKM120 +temozolomide with/without radiotherapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Fayetteville, Arkansas • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MENU Study: Online Experiment

NCT06909019
View directory record Official record
Conditions
Food Selection
Interventions
Control (QR) Labels, Low Climate Impact Labels, High Climate Impact Labels, Traffic Light Labels, Climate Grade Labels
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
6,294 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of MDMA on Social and Emotional Processing

NCT01849419
View directory record Official record
Conditions
Drug Addiction
Interventions
Within-subjects (MDMA), Within-subjects (oxytocin), Within-subjects (placebo)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

NCT03889886
View directory record Official record
Conditions
Dry Eye
Interventions
SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
26
States / cities
Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis

NCT01828086
View directory record Official record
Conditions
Chronic Plaque-type Psoriasis
Interventions
CJM112, Secukinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Anniston, Alabama • Anaheim, California • Encino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Results available

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

NCT03627195
View directory record Official record
Conditions
Schizophrenia
Interventions
DSP-1349M, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Study of the Effect of Two Experimental Lozenges on Oral Malodor After Single Use

NCT05950529
View directory record Official record
Conditions
Oral Malodor
Interventions
Experimental lozenge with the enzyme Polyphenol oxidase and green coffee extract, Experimental lozenge with the enzyme Polyphenol oxidase, green coffee extract and flavor, Placebo lozenge control (sorbitol only), No product
Other
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide

NCT00132522
View directory record Official record
Conditions
Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
Interventions
EMD 273066
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
Durate, California • Lebanon, New Hampshire • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Sep 21, 2026, 9:37 AM EDT
Recruiting Phase 2 Interventional

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

NCT05604131
View directory record Official record
Conditions
Acute Myocardial Infarction Type 1
Interventions
Deferiprone Tablets, Placebo
Drug
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years to 79 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 21, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of KINE-101 in Healthy Volunteers

NCT07343323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KINE-101, Placebo
Drug
Lead sponsor
Kine Sciences Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 21, 2026, 9:37 AM EDT